Duchenne muscular dystrophy gene carrier

7 trials 3 recruiting MedDRA PT
7 Registered trials
3 Recruiting
3 Unique sponsors
5 Unique IMPs
7 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 1
— ATC code not specified 6
Mechanism of action (INN-stem analysis)
Unknown / small molecule 5 substances
Phase III: 2 Phase II: 2 Phase I/II: 1 Phase I (Other): 1 Phase I (First in Human): 1

Filter these 7 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 7 trials

Phase III

2 trials
  • Sarepta Therapeutics Inc. Commercial
    DELANDISTROGENE MOXEPARVOVEC
    2023-505043-39-00 4 countries 2024 n=74 Orphan
    Recruiting
  • Sarepta Therapeutics Inc. Commercial
    DELANDISTROGENE MOXEPARVOVEC
    2024-512626-28-00 6 countries 2024 n=95 Orphan
    Halted

Phase II

2 trials
  • F. Hoffmann-La Roche AG Commercial
    DELANDISTROGENE MOXEPARVOVEC
    2023-509901-57-00 5 countries 2023 n=11 Orphan
    Halted
  • Sarepta Therapeutics Inc. Commercial
    VESLETEPLIRSEN
    2023-509935-23-00 5 countries 2020 n=21
    Ended

Phase I/II

1 trial
  • Entrada Therapeutics Inc. Commercial
    ENTR-601-44
    2024-517584-23-00 3 countries 2025 n=9
    Recruiting

Phase I (Other)

1 trial
  • Sarepta Therapeutics Inc. Commercial
    DELANDISTROGENE MOXEPARVOVEC; IMLIFIDASE
    2024-512624-11-00 1 country 2023 n=7 Orphan
    Ended

Phase I (First in Human)

1 trial
  • Entrada Therapeutics Inc. Commercial
    ENTR-601-45
    2024-517499-39-00 4 countries 2025 n=14
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Sarepta Therapeutics Inc. Commercial 4 Phase I (Other), Phase II, Phase III 1
Entrada Therapeutics Inc. Commercial 2 Phase I (First in Human), Phase I/II 2
F. Hoffmann-La Roche AG Commercial 1 Phase II 0
New trials by year
2020
1
2023
2
2024
2
2025
2
← All indication landscapes